- (954) 835-1500
13794 NW 4th St, Ste 212Sunrise FL 33325
Call For PriceMyocell
Bioheart’s lead product candidate is myocell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle from the patient's thigh. From this muscle specimen, muscle stem cells (also called myoblasts) are then isolated, expanded using bioheart's proprietary cell-culturing process, & injected directly into the scar tissue of the patient's heart. The cells are delivered by an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The muscle stem cells populate the regions of scar tissue & are intended to improve cardiac function by helping the heart muscle beat more efficiently.
Myocell Sdf-1Myocell Sdf-1
Call For PriceMyocell Sdf-1Myocell Sdf-1
Has received approval from the fda to begin human clinical trials & is intended to be an improvement to myocell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor – 1 or sdf-1 protein. Following injury which results in inadequate blood flow to the heart, such as a heart attack, the human body naturally increases the level of sdf-1 protein in the heart. By modifying the myoblasts to express sdf-1 prior to injection, the levels of sdf proteins in the heart can be increased. The presence of additional quantities of sdf-1 protein released by the myoblasts may stimulate the recruitment of the patient's existing stem cells to the cell transplanted area and, thereafter, the recruited stem cells will assist in the tissue repair & blood vessel formation process. In preclinical studies, myocell sdf-1 provided a 54 percent improvement of heart function compared to 27 percent for the original myocell composition, while the placebo control treated animals declined by 10 percent. The preclinical studies also demonstrated that this product candidate can enhance blood vessel formation in damaged hearts.
Call For PriceMyocath
The myocath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. It provides for multiple injections to a pre-determined needle insertion depth w/ a single core needle of 25 gauge diameter that can be advanced & retracted from the tip of the catheter. The myocath is intended for use w/ commercially available becton-dickinson 1 milliliter & 3 milliliter syringes. Although we hope to prove that myocell can be administered w/ a variety of different catheters, myocath has been specifically designed to be used for the delivery of myocell & has been used as the delivery mechanism in the majority of our clinical trials to date.
Call For PriceLipicell
Adipose (fat) tissue is readily available & has been shown to be rich in microvascular, myogenic & angiogenic cells. In collaboration w/ the regenerative medicine institute in tijuana, mexico, congestive heart failure patients are being treated in a phase i/ii trial at hospital angeles tijuana. These patients have demonstrated on average an absolute improvement of 13 percentage points in ejection fraction & an increase of 100 meters in their six minute walk distance.
Do you work here? Update this business and complete it's profile.